Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03218917

Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis

Non-Cystic Fibrosis Bronchiectasis Clinical Trial

Official title:
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy, Safety & Tolerability, and PK of INS1007 Administered Once Daily for 24 Weeks in Subjects With Non-CF Bronchiectasis - The Willow Study

Clinical Trial Summary

The purpose of the study is to evaluate if INS1007 can reduce pulmonary exacerbations over a 24-week treatment period in participants with non-cystic fibrosis bronchiectasis.

Clinical Trial Description

Phase 2 randomized, double-blind, placebo-controlled, parallel-group, multicenter, multi-national study to assess the efficacy, safety and tolerability, and pharmacokinetics (PK) of INS1007 administered once daily for 24 weeks in participants with non-cystic fibrosis bronchiectasis (NCFBE). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03218917
Study type Interventional
Source Insmed Incorporated
Contact
Status Completed
Phase Phase 2
Start date October 31, 2017
Completion date December 12, 2019
View Details
See also
  Status Clinical Trial Phase
Completed NCT01792440 - The Sputum Colour Chart as a Predictor of Lung Inflammation and Proteolysis in Non-cystic Fibrosis Bronchiectasis N/A
Active, not recruiting NCT05523180 - A Study to Evaluate the Effect of Probiotic Supplement on Quality of Life N/A
Completed NCT05495243 - Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-CF Bronchiectasis With Excess Mucus and Cough Phase 2
Recruiting NCT06237348 - Simeox Therapy at Home Versus Standard of Care in NCFB Patients With CMH N/A
Completed NCT03056326 - A Study to Investigate Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of CHF6333 in Healthy Subjects Phase 1
Not yet recruiting NCT02614300 - The Role of Pulmonary Rehabilitation and Airways Clearance Techniques in the Multidisciplinary Management of Non CF Bronchiectasis N/A
Recruiting NCT04322929 - Roflumilast in Non-CF Bronchiectasis Study (2019) Phase 2
Completed NCT05369624 - Exercise Capacity in Non-cystic Fibrosis Bronchiectasis After a Pulmonary Rehabilitation Home-based Program N/A
Completed NCT04010799 - A Clinical Study to Investigate Safety, Tolerability and Distribution of CHF 6333 After One or After Repeated Inhalation in Patients With Cystic Fibrosis (CF) and in Patients With Non Cystic Fibrosis (NCFB) Bronchiectasis Phase 1
Completed NCT03428334 - Roflumilast in Non-CF Bronchiectasis Study Phase 2
Completed NCT04656275 - A Study in Patients With Non-cystic Fibrosis Bronchiectasis to Test How Well Different Doses of BI 1323495 Are Tolerated and How BI 1323495 Affects Biomarkers of Inflammation Phase 1
Not yet recruiting NCT06151366 - Early Detection of Pulmonary Exacerbations in Non-cystic Fibrosis Bronchiectasis
Completed NCT02081963 - Combined Administration of Nebulized Amikacin in Patients With Acute Exacerbation of Non-Cystic Fibrosis Bronchiectasis Phase 4
Completed NCT02883101 - The Effects of Pulmonary Rehabilitation in Patients With Non-cystic Fibrosis Bronchiectasis N/A
Completed NCT01792427 - Mortality in Non-cystic Fibrosis Bronchiectasis N/A
Recruiting NCT04278040 - Inhalations of Ultra-low Doses of Melphalan for the Treatment of Non-cystic Fibrosis Bronchiectasis Phase 2
Active, not recruiting NCT05006573 - Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis Phase 3
Not yet recruiting NCT06352944 - Procalcitonin as a Marker of Severity of Non-cystic Fibrosis Bronchiectasis in Children
Recruiting NCT05860803 - Breathing Training and Exercise Capacity in Non-CFB N/A
Recruiting NCT05616221 - Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection Phase 2